XML 52 R37.htm IDEA: XBRL DOCUMENT v3.20.4
Supplementary Balance Sheet Information - Accrued Expenses (Details) - USD ($)
Dec. 31, 2020
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accrued compensation $ 1,523,321 $ 1,003,383
Preferred stock dividend 389,495 365,255
Clinical trials 1,557,134 1,504,660
Clinical trials 66,593 181,408
Director fees 92,500 67,500
Professional fees and outside services 38,180 21,000
Patent, license and other fees 117,440 69,950
Other accrued liabilities 66,100 46,905
Total accrued liabilities $ 3,850,763 $ 3,260,061